Ascentage Pharma Group Internat (AAPG) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $22.88, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.5): -0.5; Negative momentum.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1... Read more
Hold if already holding. Not a fresh buy at $22.88, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.5): -0.5; Negative momentum. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 111d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $22.88, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.5): -0.5; Negative momentum. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Maintain position. Not compelling to add more. Target $41.65 (+82.0%), stop $21.53 (−6.3%), A.R:R 10.4:1. Score 6.3/10, moderate confidence.
Take-profit target: $41.65 (+82.1% upside). Target $41.65 (+82.0%), stop $21.53 (−6.3%), A.R:R 10.4:1. Stop-loss: $21.53.
Leverage penalty (D/E 1.5): -0.5; Negative momentum; Below 200-MA, MA slope -5.0%/30d (confirmed downtrend).
Ascentage Pharma Group Internat trades at a P/E of N/A (forward -18.8). TrendMatrix value score: 8.5/10. Verdict: Hold.
13 analysts cover AAPG with a consensus score of 4.3/5. Average price target: $48.
What does Ascentage Pharma Group Internat do?Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic...
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.